Loading...
XTSX
RX
Market cap95mUSD
Jul 18, Last price  
11.45CAD
1D
0.44%
1Q
9.05%
Jan 2017
43.13%
Name

Biosyent Inc

Chart & Performance

D1W1MN
P/E
18.07
P/S
3.75
EPS
0.63
Div Yield, %
1.18%
Shrs. gr., 5y
-3.27%
Rev. gr., 5y
10.33%
Revenues
35m
+10.89%
748,5201,514,4911,104,3251,101,9911,029,9021,681,2102,808,6665,024,1547,799,42612,211,12715,388,19617,922,27020,762,75521,527,02821,424,32422,332,16828,618,21827,925,18731,590,30235,030,897
Net income
7m
+12.54%
505,257383,145-125,991-287,892-260,55752,160420,3921,541,3171,928,0283,154,0793,764,8894,309,5055,206,2775,705,3864,369,2953,795,3356,281,5665,458,3456,460,1277,270,104
CFO
9m
+71.39%
747,809222,25814,249-260,094-342,79237,892596,0791,249,1452,118,9343,640,0132,810,9204,399,0226,546,1316,286,5984,771,0236,894,4254,674,8884,948,7565,054,9748,663,484
Dividend
Sep 04, 20240.045 CAD/sh
Earnings
Aug 25, 2025

Profile

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
IPO date
May 22, 1981
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
35,031
10.89%
31,590
13.12%
27,925
-2.42%
Cost of revenue
24,991
23,354
20,567
Unusual Expense (Income)
NOPBT
10,039
8,236
7,358
NOPBT Margin
28.66%
26.07%
26.35%
Operating Taxes
2,512
2,074
1,972
Tax Rate
25.03%
25.18%
26.81%
NOPAT
7,527
6,162
5,386
Net income
7,270
12.54%
6,460
18.35%
5,458
-13.11%
Dividends
(2,080)
(1,913)
(484)
Dividend yield
1.60%
1.70%
0.55%
Proceeds from repurchase of equity
(5,177)
(3,629)
(3,649)
BB yield
3.99%
3.23%
4.16%
Debt
Debt current
197
183
174
Long-term debt
1,879
2,259
2,616
Deferred revenue
(1,403)
Other long-term liabilities
1,403
Net debt
(23,969)
(26,245)
(26,164)
Cash flow
Cash from operating activities
8,663
5,055
4,949
CAPEX
(42)
(174)
(519)
Cash from investing activities
3,288
884
(10,790)
Cash from financing activities
(7,829)
(5,785)
(4,371)
FCF
8,493
4,852
4,634
Balance
Cash
15,941
26,187
28,696
Long term investments
10,104
2,500
258
Excess cash
24,293
27,107
27,558
Stockholders' equity
32,864
32,473
31,134
Invested Capital
11,748
8,873
6,882
ROIC
73.00%
78.23%
83.30%
ROCE
27.77%
22.77%
21.25%
EV
Common stock shares outstanding
11,808
12,170
12,541
Price
11.00
19.31%
9.22
31.71%
7.00
-15.25%
Market cap
129,887
15.75%
112,211
27.83%
87,784
-17.43%
EV
105,918
85,966
61,621
EBITDA
10,629
8,691
7,809
EV/EBITDA
9.96
9.89
7.89
Interest
59
68
77
Interest/NOPBT
0.59%
0.83%
1.05%